Lataxin (Timolol Maleate, Latanoprost)

Lataxin is used in glaucoma therapy to reduce intra‑ocular pressure through complementary mechanisms.

• Primary open‑angle glaucoma: provides sustained IOP reduction to prevent optic nerve damage.
• Ocular hypertension: lowers elevated IOP to reduce the risk of progression to glaucoma.
• Pseudoexfoliative glaucoma: helps control IOP where single‑agent therapy is insufficient.

• Timolol maleate non‑selectively blocks β‑adrenergic receptors in the ciliary body, decreasing aqueous humor production. Latanoprost, a prostaglandin F2α analog, remodels the extracellular matrix of the uveoscleral pathway, enhancing outflow of aqueous humor. The combined actions result in a greater overall reduction of intra‑ocular pressure than either agent alone.

Lataxin may cause ocular and systemic adverse reactions.

Common Side Effects

• Eye irritation or burning sensation.
• Blurred vision shortly after instillation.
• Conjunctival hyperemia (redness).
• Itching or mild allergic eyelid dermatitis.
• Dry eye or foreign‑body sensation.
• Transient increase in IOP after initial dosing.

Serious or Rare Side Effects

• Severe allergic reaction with swelling of the eyelid or periorbital tissues.
• Persistent worsening of glaucoma despite therapy.
• Systemic beta‑blocker effects such as bradycardia, hypotension, or bronchospasm.
• Irreversible darkening of the iris or periorbital fat atrophy.
• Corneal edema or ulceration.
• Acute angle‑closure glaucoma precipitated by pupillary dilation.

Before prescribing Lataxin, clinicians should consider patient‑specific factors and monitor for adverse events.

• Cardiovascular disease: assess for bradycardia, heart block, or heart failure.
• Respiratory conditions: avoid in patients with asthma or severe COPD.
• Pregnancy and lactation: use only if potential benefit justifies the risk, as safety data are limited.
• Contact lens wear: advise removal before and after instillation to prevent lens discoloration.
• Concomitant ocular medications: evaluate for additive IOP‑lowering effects.
• Store at room temperature: keep in the original container, protect from light and moisture.

Lataxin can interact with systemic and ocular agents, altering efficacy or safety.

Major Interactions (Avoid)

• Systemic non‑selective beta‑blockers: may cause additive bradycardia or hypotension.
• Other prostaglandin analog eye drops: risk of excessive uveoscleral outflow and ocular irritation.
• Sympathomimetic agents (e.g., epinephrine eye drops): may reduce IOP‑lowering effect.

Moderate Interactions (Monitor Closely):\n- Topical anesthetics: may increase corneal toxicity when used together.

• Anticholinergic eye drops: monitor for additive dry‑eye symptoms.
• Systemic carbonic anhydrase inhibitors: watch for enhanced IOP reduction and electrolyte changes.